US 12,083,245 B2
Amniotic membrane powder and its use in wound healing and tissue engineering constructs
Sean V. Murphy, Winston-Salem, NC (US); Aleksander Skardal, Clemmons, NC (US); and Anthony Atala, Winston-Salem, NC (US)
Assigned to Wake Forest University Health Sciences, Winston-Salem, NC (US)
Appl. No. 15/515,049
Filed by WAKE FOREST UNIVERSITY HEALTH SCIENCES, Winston-Salem, NC (US)
PCT Filed Oct. 1, 2015, PCT No. PCT/US2015/053571
§ 371(c)(1), (2) Date Mar. 28, 2017,
PCT Pub. No. WO2016/054423, PCT Pub. Date Apr. 7, 2016.
Claims priority of provisional application 62/058,969, filed on Oct. 2, 2014.
Prior Publication US 2017/0203004 A1, Jul. 20, 2017
Int. Cl. A61L 27/36 (2006.01); A61K 31/726 (2006.01); A61K 35/50 (2015.01); A61K 38/17 (2006.01); A61K 38/36 (2006.01); A61K 38/39 (2006.01); A61L 26/00 (2006.01); A61L 27/20 (2006.01); A61L 27/22 (2006.01); A61L 27/24 (2006.01); A61L 27/26 (2006.01); A61L 27/52 (2006.01); A61L 27/54 (2006.01); A61L 27/60 (2006.01)
CPC A61L 27/3604 (2013.01) [A61K 31/726 (2013.01); A61K 35/50 (2013.01); A61K 38/177 (2013.01); A61K 38/36 (2013.01); A61K 38/39 (2013.01); A61L 26/0057 (2013.01); A61L 26/008 (2013.01); A61L 27/20 (2013.01); A61L 27/222 (2013.01); A61L 27/227 (2013.01); A61L 27/24 (2013.01); A61L 27/26 (2013.01); A61L 27/3641 (2013.01); A61L 27/3683 (2013.01); A61L 27/52 (2013.01); A61L 27/54 (2013.01); A61L 27/60 (2013.01); A61L 2300/236 (2013.01); A61L 2300/252 (2013.01); A61L 2300/412 (2013.01); A61L 2430/34 (2013.01)] 25 Claims
 
1. An amniotic membrane powder composition comprising an amount of total released protein in the range of 30 mg/g to 500 mg/g,
wherein the composition further comprises a cross-linked hydrogel matrix;
wherein the cross-linked hydrogel matrix comprises hyaluronic acid cross-linked to gelatin through a polyethylene glycol comprising crosslinker; and
wherein the crosslinking occurs via maleimide-thiol bonds.